

## PRODUCT:

# LOXO-101

## ALTERNATE NAME:

(3S)-N-[5-[(2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-1-pyrrolidinecarboxamide; ARRY 470; Larotrectinib


## CATALOG #:

B2291-5,25

## AMOUNT:

5 mg, 25 mg

## STRUCTURE:



## MOLECULAR FORMULA:

C<sub>21</sub>H<sub>22</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub>

## MOLECULAR WEIGHT:

428.44

## CAS NUMBER:

1223403-58-4

## APPEARANCE:

Crystalline solid

## SOLUBILITY:

DMSO (~5 mg/ml)

## PURITY:

≥98% by HPLC

## STORAGE:

Store at -20°C. Protect from air and light

## DESCRIPTION:

LOXO-101 is a potent, ATP-competitive TRK inhibitor with IC<sub>50</sub>s in low nanomolar range for inhibition of all TRK family members in binding and cellular assays, with 100-fold selectivity over other kinases, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.

## REFERENCES:

Doebele, R.C., *et al.* (2015). *Cancer Discov.* **5**, 1049-1057.

## HANDLING:

Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

## RELATED PRODUCTS:

GW-441756 (**B1147**)

Belizatinib (TSR-011) (**B2028**)

Entrectinib (**B1324**)

GNF-5837 (**B1339**)

Lestaurtinib (**1805**)

LOXO-101 (**B2291**)

## USAGE:

**FOR RESEARCH USE ONLY! Not to be used in humans**